癌に関連した線維芽細胞と骨肉腫細胞の悪性対話:マイクロ環境媒介薬剤耐性および治療標的
Xiufeng Wang1, Cong Luo1, Danying Zhang2
1Department of Orthopedic Trauma, Zhuji People's Hospital of Zhejiang Province, Shaoxing, China.
Frontiers in immunology
|September 5, 2025
まとめ
癌に関連した線維細胞 (CAF) は,腫瘍の微小環境 (TME) を変化させ,骨肉腫 (OS) の成長と治療耐性を促進する. 新しい治療法でCAFをターゲットにすることは,OSの治療結果を改善するための有望な戦略です.
科学分野:
- 腫瘍学
- 癌 生物学
- 腫瘍の微小環境の研究
背景:
- 癌に関連した線維細胞 (CAF) は,腫瘍の微小環境 (TME) の主要な調節体である.
- CAFは,骨肉腫 (OS) の免疫抑制性および化学抵抗性に影響を及ぼします.
研究 の 目的:
- オステオサルコマの進行を促すCAFの多面的な役割を検討する.
- パラクリンシグナル伝達,ECM再構成,代謝再プログラムを含むCAF媒介メカニズムを探求する.
- OSの治療を改善するために,CAFを標的とした新興の治療戦略について議論する.
主な方法:
- オステオサルコマにおけるCAFに関する研究の文献レビュー.
- CAFの異質性とその治療耐性への影響の分析
- 新しい治療薬と組み合わせ戦略の評価
主要な成果:
- CAFは,パラクリン因子 (TGF-β,IL- 6),ECM再構成,および代謝再プログラムを通じてOSの進行を促進する.
- CAFの異質性 (myCAFs, iCAFs) は,TME内の多様な機能に寄与する.
- FAP阻害剤やTGF-β阻害剤のような新興治療法は,臨床前モデルで潜在性を示しています.
結論:
- CAFは骨肉腫の進行と治療抵抗の重要な原動力です.
- CAFの異質性と機能をターゲットにすることは,化学抵抗を克服するための実行可能な戦略です.
- CAF阻害剤,免疫療法,化学療法を含む組み合わせ治療は,OSの精密治療に有望である.
関連する概念動画
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


